Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy

Australasian Journal of Dermatology

Volumn 43, Issue 4, 2002, Pages 262-268

  Ng, Chee H ^c   Tam, Mei M ^c   Celi, Elizabeth ^c   Tate, Bruce ^a   Schweitzer, Isaac ^b  

^a WESTERN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NONE

Author keywords

Acne therapy; Adverse effects; Causal relationship; Depression

Indexed keywords

ANTIBIOTIC AGENT; ISOTRETINOIN; TOPICAL AGENT;

ACNE VULGARIS; ADULT; AGE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOOD; PILOT STUDY; PREDICTION; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DEPRESSION; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; MINOCYCLINE; NAPHTHALENES; QUALITY OF LIFE;

EID: 0036436821     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2002.00612.x     Document Type: Article

References (30)

1. Nguyen EH, Wolverton SE. Systemic retinoids. In: Wolverton SE (ed). Comprehensive Dermatologic Drug Therapy. Philadelphia: WB Saunders, 2001; 269-310.
2. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid: Evaluation of sebum production and the clinical response in a multiple-dose trial. J. Am. Acad. Dermatol. 1980; 3: 602-11.
3. Mills CM, Marks R. Adverse reactions to oral retinoids. Drug Saf. 1993; 9: 280-90.
4. Bigby M, Stern RS. Adverse reactions to isotretinoin. J. Am. Acad. Dermatol. 1988; 18: 543-52.
5. Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: Prospective evaluation of adverse events. J. Cutan. Med. Surg. 2000; 4: 66-70.
6. Lamberg L. Acne drug depression warnings highlight need for expert care. JAMA 1998; 279: 1073.
7. Wysowski DK, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin. N. Engl. J. Med. 2001; 344: 460.
8. Ault A. Isotretinoin use may be linked with depression. Lancet 1998; 351: 730.
9. Byrne A, Hnatko G. Depression associated with isotretinoin therapy. Can. J. Psychiatry 1995; 40: 567.
10. Scheinman PL, Peck GL, Rubinow DR, DiGiovanna JJ, Abangan DL, Ravin PD. Acute depression from isotretinoin. J. Am. Acad. Dermatol. 1990; 22: 1112-14.
11. Gatti S, Serri F. Acute depression from isotretinoin. J. Am. Acad. Dermatol. 1991; 25: 132.
12. Peck GL, DiGiovanna JJ, Rubinow DR. Acute depression from isotretinoin, reply. J. Am. Acad. Dermatol. 1991; 25: 132.
13. Hazen PG, Carney JF, Walker AE, Stewart JJ. Depression - A side effect of 13-cis-retinoic acid therapy. J. Am. Acad. Dermatol. 1983; 6: 278-9.
14. Ng CH, Tam MM, Hook SJ. Acne, isotretinoin treatment and acute depression. World J. Biol. Psychiatry 2001; 2: 159-61.
15. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch. Dermatol. 2000; 136: 1231-6.
16. Wysowski DK, Beitz J. Methodological limitations of the study 'Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide'. Arch. Dermatol. 2001; 137: 1102-3.
17. Koo J. The psychosocial impact of acne: Patients' perception. J. Am. Acad. Dermatol. 1995; 32: 26-30.
18. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br. J. Dermatol. 1998; 139: 846-50.
19. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br. J. Dermatol. 1999; 140: 273-82.
20. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with isotretinoin. J. Am. Acad. Dermatol. 1987; 17: 25-32.
21. Macdonald Hull S, Cunliffe WJ, Hughes BR. Treatment of the depressed and dysmorphophobic acne patient. Clin. Exp. Dermatol. 1991; 16: 210-11.
22. Layton AM, Seukeron D, Cunliffe WJ. Scarred for life. Dermatology 1997; 195: 29-33.
23. Cutler TP (ed.). A Suitable Case for Treatment? Oxford: Oxford Medical Education Services, 1985; 15-17.
24. Zich JM, Attkisson CC, Greenfield TK. Screening for depression in primary care clinics: The CES-D and the BDI. Int. J. Psychiatry Med. 1990; 20: 259-77.
25. Cavanaugh S, Clark DC, Gibbons RD. Diagnosing depression in the hospitalised medically ill. Psychosomatics 1983; 24: 809-15.
26. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol. Med. 1998; 28: 551-8.
27. Murphy B, Herrman H, Hawthorne G, Pinzone T, Evert H. Australian WHOQOL Instruments: User's Manual and Interpretation Guide. Australian WHOQOL Field Study Centre, 2000 [Accessed 1 October 2001]; 1-48. Available from: http:// www.svhm.org.au/whoqol/
28. Henderson S, Andrews G, Hall W. Australia's mental health: An overview of the general population survey. Aust. NZ J. Psychiatry 2000; 34: 197-205.
29. Patton GC, Coffey C, Posterino JB, Wolfe R. Adolescent depressive disorder. A population-based study of ICD-10 symptoms. Aust. NZ J. Psychiatry 2000; 34: 741-7.
30. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J. Am. Acad. Dermatol. 2001; 45: 515-19.